Drugs / SI-B036
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07678970 | Jul 2026 → Dec 2028 expected | digestive system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07606612 | Jun 2026 → Dec 2028 expected | neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-15 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于SI-B036双特异性抗体注射液治疗局部晚期或转移性实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-15 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于SI-B036双特异性抗体注射液治疗局部晚期或转移性实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SI-B036 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07606612 ↗ |
| Route | Intravenous | “Administration by intravenous infusion” NCT07606612 ↗ |